Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Fintel reports that on July 29, 2025, Barclays upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Fintel reports that on July 29, 2025, JP Morgan upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

US stocks closed in the red Tuesday as investors digested a wave of corporate earnings and economic data, while bracing for ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 20.2% in the morning session after the company ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Wall Street traders sent stocks lower in the run-up to the Federal Reserve decision, with concerns about high valuations ...

Desai believes it's a "good time for fixed income," but wants to see more realistic investor expectations. Generations out there in the past got accustomed to getting just 1% -2.5% for investing in 10 ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for ...

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...